Review
Copyright ©The Author(s) 2023.
World J Gastrointest Oncol. Jan 15, 2023; 15(1): 1-18
Published online Jan 15, 2023. doi: 10.4251/wjgo.v15.i1.1
Table 3 Ongoing clinical trials investigating systemic therapy and/or local regional therapy against hepatocellular carcinoma
Clinical trials number
Study type
Agent(s)
Local regional therapy
Estimated enrollment
Primary endpoint
chiCTR2100044057Phase IICamrelizumab + BevacizumabMicrowave Ablation30PFS
chiCTR2100046533ProspectiveApatinib + CamrelizumabTACE37PFS
NCT05162898ProspectiveToripalimab + LenvatinibRadiofrequency Ablation90PFS
NCT05010434Phase IISintilimab + BevacizumabRadiofrequency AblationORR
NCT05444478ProspectiveLenavatinibMicrowave Ablation2743-yr PFS%
NCT05277675ProspectiveTislelizumab/Sintilimab + Lenvatinib/BevacizumabRadiofrequency Ablation1601-yr PFS%
NCT05162898ProspectiveToripalimab + LenvatinibRadiofrequency ablation90RFS
NCT04663035Phase IITislelizumabAblation1201-yr PFS%
NCT05355155Phase IIBevacizumab + Biosimilar IBI305-15ORR
NCT05103904Phase IILenvatinib-19ORR
NCT04615143ProspectiveTislelizumab/Tislelizumab + Levatinib-80PFS
NCT04564313Phase ICamrelizumab-20ORR
NCT04237740Phase IIIRelenvatinib-403-yr PFS%
NCT04204850Phase IICabozantinib20DCR